Muscarinic acetylcholine receptors (mAChRs) are central to the modulation of neurotransmission in the human brain and are emerging as promising targets in the management of neuropsychiatric disorders.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Suven Life Sciences Ltd. has received IND approval from the FDA allowing it to initiate a first-in-human phase I study of SUVN-I6107, a muscarinic M1 receptor positive allosteric modulator (PAM) as a ...

Myopia, a leading cause of visual impairment globally, can progress to serious complications like retinal and choroidal degeneration. While atropine is commonly used to manage childhood myopia, its ...

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adultsOral ANAVEX®3-71 tablet ...

Neumora Therapeutics, Inc. has announced the initiation of a Phase 1 study for NMRA-861, a potent and selective positive allosteric modulator of the M4 muscarinic receptor, aimed at treating ...

Multiple sclerosis (MS) degrades the protective insulation around nerve cells, leaving their axons, which carry electrical impulses, exposed like bare wires. This can cause devastating problems with ...

Schizophrenia is a chronic psychiatric disorder that requires lifelong management, with consistent medication adherence essential to prevent relapse and disability. Counseling that emphasizes empathy, ...